Lindsay S. Ackerman, MD, FAAD

The latest ABCs of Dermatology explored the future potential of amlitelimab in atopic dermatitis and the potential of OX40 ligand-targeted therapy.

Amlitelimab was discussed in the ABCs in Dermatology podcast, with the hosts highlighting atopic dermatitis patient demographics and high disease burden.

Explore OX40/OX40L inhibition in atopic dermatitis: phase 3 amlitelimab efficacy, safety signals, and what upstream immune control could mean.

Ackerman offers a broad perspective on how psoriatic treatment is shifting, from oral IL-23 inhibitors to the emerging role of incretin therapy in psoriatic disease.

Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.

Chris Bunick, MD, PhD, and Lindsay Ackerman, MD, preview the 2026 American Academy of Dermatology Annual Meeting.

Hosts reveal how research, mentors, and clinic rotations spark a passion for skin disease and what makes dermatology unique.

A clip from an episode of ABCs in Dermatology showcases perspective into the personal lives of hosts Chris Bunick, MD, PhD, and Lindsay Ackerman, MD.

Experts unpack biologics, molecular know-how, and patient trust—plus key previews for the upcoming AAD Annual Meeting.

Lindsay Ackerman, MD, explores novel agents and the potential of biomarkers to personalize treatment selection in psoriasis.

Lindsay Ackerman, MD, critiques traditional clinical trial models and proposes ways to improve their relevance to real-world patient populations.

Lindsay Ackerman, MD, discusses how biologic selection can be tailored based on disease distribution, symptom burden, and patient quality-of-life goals.

Lindsay Ackerman, MD, provides insights into optimizing sequencing strategies when patients fail to achieve desired outcomes with oral treatments.

Lindsay Ackerman, MD, highlights clinical strategies for addressing psoriasis in challenging or visible areas such as the scalp, nails, and genitals.

Lindsay Ackerman, MD, outlines how clinicians balance efficacy, tolerability, and patient preference when initiating first-line therapy.

Lindsay Ackerman, MD, discusses how efficacy, safety, and patient suitability differ between oral agents and advanced biologics for psoriasis.

Lindsay Ackerman, MD, examines how comparative and real-world data inform treatment decisions and shape confidence in long-term management strategies.

Lindsay Ackerman, MD, explores key clinical and patient-centered factors guiding therapy selection in psoriasis management.

Lindsay Ackerman, MD, discusses how advancements in biologic and small molecule therapies are redefining treatment goals and patient outcomes in moderate to severe psoriasis.

Panelists discuss how to effectively onboard patients to Janus kinase (JAK) inhibitors through transparent risk discussions, early follow-up visits at 4 weeks, and personalized treatment approaches that consider patient-reported outcomes and the “3 Cs” (cancer, cardiac disease, clotting disease) while emphasizing the anti-inflammatory benefits and quality-of-life improvements these therapies provide.

Panelists discuss how Janus kinase (JAK) inhibitors demonstrate a favorable safety profile across age groups and comorbid populations, with potential cardioprotective benefits due to their anti-inflammatory effects, while addressing common concerns about the boxed warning by emphasizing that only herpes zoster reactivation, tuberculosis, and nonmelanoma skin cancer show increased rates across all indications.

Panelists discuss how abrocitinib demonstrated superior efficacy compared with dupilumab in head-to-head trials, with 77% of dupilumab nonresponders achieving Eczema Area and Severity Index 75 (EASI-75) after switching to abrocitinib for 12 weeks, supported by real-world registry data showing consistent outcomes across diverse patient populations.

Panelists discuss how the Level Up study demonstrated that patients who didn’t achieve Eczema Area and Severity Index 75 (EASI-75) on dupilumab could be successfully switched to upadacitinib without washout, with two-thirds achieving EASI-75 and one-third achieving EASI-90 within just 4 weeks of switching.

Panelists discuss how switching from biologics to Janus kinase (JAK) inhibitors should be considered when patients don’t achieve adequate disease control within 3 to 6 months, experience tolerability issues, or continue to have significant quality-of-life impacts despite apparent skin improvement.

Panelists discuss how oral Janus kinase (JAK) inhibitors offer advantages over biologics in specific clinical scenarios including patients needing rapid onset of action, those with comorbid arthralgia, head and neck involvement, needle fatigue, and environmental trigger sensitivity due to their broad anti-inflammatory effects.

Panelists discuss how the AHEAD recommendations establish evidence-based treatment targets requiring simultaneous achievement of skin clearance (Eczema Area and Severity Index [EASI]-90) and itch relief (itch score 0-1) within 3 to 6 months, fundamentally changing the standard of care by incorporating patient-reported outcomes alongside physician assessments.

Panelists discuss how Janus kinase (JAK) inhibitors represent a revolutionary advancement in atopic dermatitis treatment by targeting multiple cytokine pathways simultaneously at the intracellular level, offering broader therapeutic coverage than biologics that target only 1 or 2 specific cytokines.

Latanya Benjamin, MD, and Lindsay Ackerman, MD, joins The Medical Sisterhood in a live recording at AAD 2025 to discuss advocacy, mentorship, and empowerment.

A group of 9 experts reflect on what they are looking forward to most in 2025 following the AAD annual meeting.

Looking to the future of atopic dermatitis treatment, the panel discusses ongoing research and promising emerging therapies.